Richard Aranda - 01 Oct 2025 Form 4 Insider Report for Gossamer Bio, Inc. (GOSS)

Signature
/s/ Jeff Boerneke, Attorney-in-Fact
Issuer symbol
GOSS
Transactions as of
01 Oct 2025
Net transactions value
$0
Form type
4
Filing time
02 Oct 2025, 16:13:26 UTC
Previous filing
06 Mar 2025
Next filing
05 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aranda Richard Chief Medical Officer 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO /s/ Jeff Boerneke, Attorney-in-Fact 02 Oct 2025 0001867872

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GOSS Common Stock Award $0 +162,500 +79% $0.000000 369,356 01 Oct 2025 Direct F1
holding GOSS Common Stock 2,539 01 Oct 2025 By family trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer.